Is atezolizumab plus bevacizumab with chemotherapy effective for non-small cell lung cancer with EGFR- or ALK-alteration?
@article{ACTR9451, author = {Yu Saida and Satoshi Watanabe and Toshiaki Kikuchi}, title = {Is atezolizumab plus bevacizumab with chemotherapy effective for non-small cell lung cancer with EGFR- or ALK-alteration?}, journal = {AME Clinical Trials Review}, volume = {2}, number = {0}, year = {2024}, keywords = {}, abstract = {}, issn = {3005-6152}, url = {https://actr.amegroups.org/article/view/9451} }